Small cell lung cancer – State of the art and future perspectives
Fernando J Barata1
Ana Filipa Costa1
Resumo
Em Portugal, o cancro do pulmão é a principal causa de morte entre as neoplasias. Em 2006 são previstos mais de 3500 novos casos, dos quais 20% serão diagnosticados como carcinoma do pulmão de pequenas células (CPPC). Destes, 25% a 30% dos doentes serão estadiados como doença localizada ou regional. Para estes, a opção terapêutica passa pela combinação da radioterapia (50 Gy ou 60 Gy) diária e quimioterapia. A radioterapia hiperfraccionada, em consequência da sua toxicidade, está limitada a doentes seleccionados. A combinação etopósido e cisplatina é sinérgica, bem tolerada. É o regimen standard quer na opção concomitante com a radioterapia, quer isoladamente na doença disseminada. Apesar da quimiossensibilidade e radiosensibilidade, o prognóstico global do CPPC é pobre. Há um desenvolvimento precoce de resistência associado a uma elevada predisposição para a recidiva. A terapêutica de segunda linha para o CPPC é um problema real e actual. Topotecano é hoje uma opção efectiva e bem tolerada no tratamento em segunda linha do CPPC. Há um aumento significativo da sobrevivência mediana versus a terapêutica sintomática. A sua eficácia é comparável ao clássico regimen CAV. Mostra boa tolerabilidade mesmo quando administrado em doentes idosos, com PS=2. Continua a ser bem tolerado e eficaz quando combinado com a radioterapia holocraniana cerebral ou quando administrado num esquema semanal. Com novas classes de fármacos, como agentes antiangiogénicos como o bevacizumab, inibidores da tirosina quinase e talidomida, decorrem ensaios avaliando a sua associação com a clássica quimioterapia em doentes com CPPC disseminada.
Palavras-Chave: Carcinoma pulmonar de pequenas células, CPPC, cancro do pulmão, topotecano
Abstract
]]> Lung cancer is the leading cause of cancer related death in Portugal. Almost 3500 Portuguese are expected to be diagnosed with lung cancer in 2006; approximately 20% will have small cell lung cancer (SCLC). At presentation, 25% to 30% of patients will have local or regional disease, classified as limited stage disease. The concurrent chemovalidation therapy is the best choice. Once daily thoracic radiation therapy to doses in the range of 50 Gy to 60 Gy would reflect an accepted standard of care in daily practice. Because of the increase toxicity associated with hyper fractionated radiation, this approach is often limited to select patients. Etoposide plus cisplatin are synergistic, well tolerated and result in equal or superior survival compared with other regimens. This is the standard regimen for concomitant therapy in limited stage and for extensive disease SCLC. Despite good chemo sensitivity and radio sensitivity, the prognosis of SCLC is very poor because of the early development of resistance and the associated high tendency to recurrence, making second line treatment of SCLC a problem of real medical relevance. Topotecan now offers an effective and well tolerated monosubstance for second line therapy of recurrent SCLC. There has been a significant increase in median survival for patients with SCLC receiving topotecan plus symptomatic therapy sversus symptomatic therapy. The efficacy of this drug is comparable to the efficacy of the three-drug combination CAV. The tolerability can be improved by means of toxicity-adapted dosing. In elderly and in patients with performance status 2, topotecan is also well tolerated and has good efficacy. Initial studies into weekly administration also demonstrate good efficacy. The combination of topotecan with cranial radiotherapy is well tolerated and effective in the treatment of cerebral metastases of SCLC. New classes of agents, such as antiangiogenic agents including bevacizumab, small molecule tyrosine kinase inhibitors and thalidomide are being evaluated with chemotherapy for patients with extensive stage SCLC.Key-Words: Small cell lung cancer, lung cancer, topotecan, SCLC
Texto completo disponível apenas em PDF.
Full text only available in PDF format.
Bibliografia / Bibliography
1. Schottenfeld D, Searle JG. The etiology and epidemiology of lung cancer. In Lung Cancer. Principles and Practice. Lippincort Williams & Wilkins 2005; 1: 3-24. [ Links ]
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000 – cancer incidence mortality and prevalence worldwide. IARC Press 2000.
]]> 3. Dineen KM, Silvestri GA. The Epidemiology of Lung Cancer. Malignant Tumors of the Lung. Editors Jean Paul Scullier and Willard Fry. Springer 2004; 4: 57-75.4. European Lung White Book – Major Respiratory Diseases – Lung Cancer – European Respiratory Society 2003; 4: 43-53.
5. Ma X, Tucker MA. Epidemiology of Cancer in Cancer – Principles & Practice of Oncology 7.ª edition – DeVita VT, Hellman S, Rosenberg SA – 2005; 11:217-26.
6. Jemal A, Ward EM, Thun MJ. Epidemiology of Cancer in Cancer – Principles & Practice of Oncology 7.ª edition – DeVita VT, Hellman S, Rosenberg SA. 2005; 11:226-41.
7. Registo Oncológico Regional, 1998 – IPOFG – Coimbra.
8. Levi F, Luccini F, Negri E, Boyle P. Cancer Mortality in Europe 1990-1994 and an overview of trends fron 1955 to 1994. Eur J Cancer 1999; 35: 1477-516.
9. Kreuzer M. Lung Cancer in Woman – 10th Central European Lung Cancer Conference. Lung Cancer 2006; 52 (supll2): S7-S8.
10. Gray N, Kozlowski LT. More on the regulation of tobacco smoke: how we got here and where next. Ann Oncol 2003; 14: 353-7.
11. Boffetta P. Involuntary smoking and lung cancer. Scand J. Work Hearth 2002; 28 (Suppl2): 30-40.
12. Stupp R, Monnerat C, Turrisi AT, Perry MC. Small Cell Lung Cancer: state of art and future perspectives. Lung Cancer 2004; 45: 105-17.
]]> 13. Barata FJ. Carcinoma Pulmonar de pequenas células – Quimioterapia como tratamento da doença disseminada primária e recidivante. Rev Port Pneumol 2002; VIII (4): 341-9.14. Spira A, Ettinger DS. Multidisciplinary Management of Lung Cancer. New Engl. J. Med 2004; 350 (4); 379-92.
15. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ et al. Topotecan versus cyclofosfamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 1999; 17:658-67. Scullier and Willard Fry. Springer 2004; 9: 119-38.
17. Melo MJS. Clinica e imagem do cancro do pulmão – Tratado de Pneumologia (Edits.: Maria JM Gomes e Renato Sotto Mayor). Sociedade Portuguesa de Pneumologia 2003; 85: 1137-48.
18. Barata FJ. Diagnóstico e Estadiamento – Tratado de Pneumologia (Edits.: Maria JM Gomes e Renato Sotto-Mayor). Sociedade Portuguesa de Pneumologia 2003; 86: 1149-67.
19. Micke P, Faldum A, Metz T et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer – what limits limited disease? Lung Cancer 2002; 37: 271-6.
20. Argiris A, Murren JR. Staging and Clinical Prognostic Factors for Small Cell Lung Cancer. Cancer Journal 2001; 7(5): 437-47.
21. Fox W, Scalding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small cell carcinoma. Lancet 1973; 2:63.
22. Davis S, Crino L, Tonato M et al. A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small cell lung cancer. Am J Clin Oncol 1993; 16:93.
23. Hauber HP, Bohuslavizki KH, Lund CH et al. Positron Emission tomography in the staging of small cell lung cancer. Chest 2001; 119:950-4.
]]> 24. Bradley JD, Dehdashti F, Mintun MA. Positron Emission Tomography in Limited Stage Small Cell Lung Cancer: A Prospective Study. J Clin Oncol 2004; 22(16): 3248-54.25. Dearing MP, Steinberg SM, Phelps R et al. Outcome of patients with small cell lung cancer – effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol 1990; 8:1042-9.
26. Spiegelman D, Maurer LH, Ware JH et al. Prognostic factors in small cell carcinoma of the lung: an analysis of 1521 patients. J Clin Oncol 1989;7:344-54.
27. Paesmans M, Scullier JP, Leconte J et al. Prognostic factors for patients with small cell carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33.
28. Quoix E, Pirohit A, Faller-Beau M et al. Comparative Prognostic Value of Lactate Dehydrogenase and Neuron Specific Enolase in Small Cell Lung Cancer Patients treated with platinum based Chemotherapy. Lung Cancer 2000; 30(2): 127-34.
29. Osterlink K. LDH or NSE or LDH and NSE as pretreatment prognostic factors in small cell lung cancer? A Commentary. Lung Cancer 2000; 30: 51-5.
30. Blackhall FH, Pintilie M, Michael M et al. Expression and prognostic significance of kit, protein kinase B and mitogen activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 2003; 9: 2241-7.
31. Martin B, Paesmans M, Berghmans T et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of literature with meta-analysis. Br J Cancer 2003;89:55-64.
32. Pingnon JP, Arriagada R, IhdeD et al. A Meta-analysis of thoracic radiotherapy for small cell lung cancer. N Eng J Med 1992; 327:1618.
33. Fried DB, Morris DL, Poole C et al. Systemic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited stage small cell lung cancer. J Clin Oncol 2004;22:4785-93.
]]> 34. Turrisi AT, Kim K, Blum R et al. Twice daily compared with once daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Eng J Med 1999;340:265-71.35. Schild SE, Bonner JA, Shanahan TG et al. Long term results of a phase III trial comparing once daily radiotherapy with twice daily radiotherapy in limited stage small cell lung cancer. J Radiat Oncol Biol 2004;59:943-51.
36. Blackstock AW, Bogart JA, Matthews C et al. Split course versus continuous thoracic radiation therapy for limited stage small cell lung cancer: Final Report of a randomized phase III trial. Clin Lung Cancer 2005; 6:287-92.
37. Urbanic JJ, Blackstock AW. Radiotherapy for patients with Limited Stage Small Cell Lung Cancer – Educational Book. 2006 American Society Clinical Oncology.
38. Auperin A, Arriagada R, Pignon JP et al. Prophylatic cranial irradiation for patients with limited small cell lung cancer in complete remission. N Eng J Med 1999; 341:476-84.
39. Ettinger DS, Finfelstein DM et al. A Randomized comparision of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive stage small cell lung cancer: a phase III study of Eastern Cooperative Oncology Group. J Clin Oncol 1990; 8: 230-40.
40. Von Pawel J. The role of topotecan in treating small cell lung cancer: second line treatment. Lung Cancer 2003; 41(4), S3-S8.
41. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Eng J Med 2002; 346: 85-91.
42. Hanna N, Einhorn L, Sandler A et al. Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) as treatment for chemotherapy naïve patients with extensive disease small cell lung cancer. J.Clin. Oncol 2005; 23:622s.
43. Okamoto H, Watanabe K, Kunikane H et al. Randomized phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor risk patients with extensive disease small cell lung cancer. J Clin Oncol 2005;23; 623S.
]]> 44. Ardizzoni A, Favaretto A, Boni L et al. Platinun-etoposide chemotherapy in elderly patients with small cell lung cancer. J Clin Oncol 2005; 23: 569-75.45. Sculier J, Bergman T, Castaigne C et al. Maintenance chemotherapy for small cell lung cancer. A critical review of the literature. Lung Cancer 1998; 19:141-51.
46. Schutte W. Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer 2001; S99: 107.
47. Eckardt JR. Second Line Treatment of Small Cell Lung Cancer. Oncology 2003; 17:2.
48. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternating of these two regimens in extensive small cell lung cancer. J Clin Oncol 1992; 10:282-91.
49. Giaconne G. Second line chemotherapy in small cell lung cancer. Lung Cancer 1989; 5:207-13.
50. Burris HA, Hanauske AR, Johnson RK et al. Activity of Topotecan, a new topoisomerase I inibitor, against human tumor colony forming units. J Nat Cancer Inst 1992; 84:1816-20.
51. Greco FA. Topotecan as first line therapy for small cell lung cancer. Lung Cancer 2003; 41 Supl 4:S9-S16.
52. Ardizonni A, Hansen H, Gamucci T et al. Topotecan, a new active drug in the second line treatment of small cell lung cancer. A phase II study in patients with refractory and sensitive disease. J. Clin. Oncol 1997; 15:2090-6.
53. Cesano A, Lane SR, Poulin R et al. Stabilization of disease as a useful predictor of survival following second line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 1999; 15:1233-8.
]]> 54. Hui Huang C, Treat J et al. New advances in Lung Cancer Chemotherapy: Topotecan anda the Role of Topoisomerases I Inibitors. Oncology 2001; 61(1):14-24.55. Huber R, Reck M, Gosse H et al. Reduced toxicity with adjusted topotecan therapy is not associated with decreased efficacy. A multicenter phase II trial in recurrent small cell lung cancer. Ann Oncol 2005; 20.
56. Mavroudis D, Veslemes K, Kouroussis C et al. Cisplatin-etposide alternating with topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II trial. Lung Cancer 2002; 38:59-63.
57. Felip E, Rosell R, Domine M et al. Sequencial dosedense paclitaxel followed by topotecan in untreated extensive disease small cell lung cancer: a Spanish Lung Cancer Group phase II study. Ann Oncol 2003;14:1549-54.
58. Steward DJ. Foreword. New Directions for topotecan in Lung Cancer Treatment. The Oncologist 2004;9 (6):1-3.
59. Treat J. Weekly topotecan in the management of lung cancer. Lung Cancer 2003; 41(4):S27-S31.
60. Eckardt JR. Emerging Role of Weekly Topotecan in Recurrent Small Cell Lung Cancer. The Oncologist 2004;9(6):25-32.
61. Kasturi VK, Eckardt JR, Greco FA. A preliminary retrospective analysis of weekly topotecan in recurrent small cell lung cancer. Proceeding ASCO 2004; 23:7359.
62. Greco FA, Burris III Ha, Yardley DA et al. Phase II tria of weekly topotecan in the second line treatment of small lung cancer. Lung Cancer 2003;41 (3):S237.
63. Seifart U, Jensen K, Ukena J et al. Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer 2005;48:415-22.
]]> 64. Treat J, Chao HH, Lane SR et al. Topotecan in the treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status. The Oncologist 2004; 9:173-81.65. Gralla. RJ. Quality-of-life Considerations in Patients with advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life. The Oncologist 2004; 9(6):14-24.
66. Armstrong DK, Spriggs D, Levin J, Lane S et al. Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An integrated Analysis. The Oncologist 2005; 10:686-94.
67. O’Brian M, Tsekov H, Ciuleanu T et al. Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC. Lung Cancer 2005;49(2):S54.
68. Frasci G, Nicollela G, Cornella P et al. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte colony stimulating factor support for patients with extensive disease small cell lung cancer. Br J Cancer 2001; 4;84(9):1166-71.
69. Stathopoulos GP, Christodoulou CH, Skarlos D et al. Second line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study. Cancer Chemother Pharmacol 2005.
70. Eckhardt J, Von Pawel J, Manikhas G et al. Comparable activity with oral topotecan/cisplatin and IV etoposide/cisplatin as treatment for chemotherapy patients with extensive disease small cell lung cancer. Final results. J Clin Oncol 2005; 22:621s.
71. Grossi F et al. The role of systemic chemotherapy in the treatment of brain metastases from small cell lung cancer. Clinical Reviews in Oncology/Hematology 2001; 37:61-7.
72. Korfel A et al. Response to topotecan of symptomatic brain metastases of small cell lung cancer also after whole brain irradiation. A Multicentre phase II study. European Journal of Cancer 2002; 38:1724-1729.
73. Wong ET, Berkenblit A. The role of Topotecan in the treatment of Brain Metastases. The Oncologist 2004;9:68-79.
]]> 74. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non small cell lung cancer. N Engl J Med 2005;353:123-32.75. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non small cell lung cancer. J Clin Oncol 2004;22:2184-91.
76. Jonson BE. Potentially effective targeted agents for patients with small cell lung cancer. Educational Book, 2006; ASCO: 449-51.
77. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
78. Rudin CM, Kozloff M et al. Phase I study og G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin/etoposide in SCLC. J Clin Oncol 2004;22:1110-7.
1 Serviço de Pneumologia. Centro Hospitalar de Coimbra.
Recebido para publicação/received for publication: 06.10.31
Aceite para publicação/accepted for publication: 07.03.26
]]>
]]>